JP6812511B2 - フィブリノゲン製剤 - Google Patents
フィブリノゲン製剤 Download PDFInfo
- Publication number
- JP6812511B2 JP6812511B2 JP2019135198A JP2019135198A JP6812511B2 JP 6812511 B2 JP6812511 B2 JP 6812511B2 JP 2019135198 A JP2019135198 A JP 2019135198A JP 2019135198 A JP2019135198 A JP 2019135198A JP 6812511 B2 JP6812511 B2 JP 6812511B2
- Authority
- JP
- Japan
- Prior art keywords
- plasma
- fibrinogen
- preparation
- sealant
- precipitate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010049003 Fibrinogen Proteins 0.000 title claims description 188
- 102000008946 Fibrinogen Human genes 0.000 title claims description 188
- 229940012952 fibrinogen Drugs 0.000 title claims description 187
- 238000002360 preparation method Methods 0.000 title claims description 108
- 210000002381 plasma Anatomy 0.000 claims description 136
- 239000000203 mixture Substances 0.000 claims description 65
- 239000000565 sealant Substances 0.000 claims description 50
- 238000009472 formulation Methods 0.000 claims description 48
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 40
- 108090000190 Thrombin Proteins 0.000 claims description 32
- 229960004072 thrombin Drugs 0.000 claims description 31
- 108010073385 Fibrin Proteins 0.000 claims description 28
- 102000009123 Fibrin Human genes 0.000 claims description 28
- 229950003499 fibrin Drugs 0.000 claims description 28
- 239000002244 precipitate Substances 0.000 claims description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- 241001465754 Metazoa Species 0.000 claims description 12
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 10
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 10
- 239000004471 Glycine Substances 0.000 claims description 5
- 229920000669 heparin Polymers 0.000 claims description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 3
- 229960002897 heparin Drugs 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- 210000004623 platelet-rich plasma Anatomy 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 238000003860 storage Methods 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 53
- 239000000306 component Substances 0.000 description 47
- 210000004369 blood Anatomy 0.000 description 21
- 239000008280 blood Substances 0.000 description 21
- 108010094028 Prothrombin Proteins 0.000 description 16
- 239000000523 sample Substances 0.000 description 16
- 108010054218 Factor VIII Proteins 0.000 description 13
- 102000001690 Factor VIII Human genes 0.000 description 13
- 241000700605 Viruses Species 0.000 description 13
- 239000003599 detergent Substances 0.000 description 13
- 229960000301 factor viii Drugs 0.000 description 13
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 238000002156 mixing Methods 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 208000032843 Hemorrhage Diseases 0.000 description 9
- 230000000740 bleeding effect Effects 0.000 description 9
- 108010073651 fibrinmonomer Proteins 0.000 description 8
- 230000035876 healing Effects 0.000 description 8
- 230000023597 hemostasis Effects 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 230000015271 coagulation Effects 0.000 description 7
- 238000005345 coagulation Methods 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 238000006116 polymerization reaction Methods 0.000 description 7
- 238000007789 sealing Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 108010014173 Factor X Proteins 0.000 description 6
- 102000013566 Plasminogen Human genes 0.000 description 6
- 108010051456 Plasminogen Proteins 0.000 description 6
- 102100027378 Prothrombin Human genes 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 229940039716 prothrombin Drugs 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 102000004506 Blood Proteins Human genes 0.000 description 5
- 108010017384 Blood Proteins Proteins 0.000 description 5
- 108010071289 Factor XIII Proteins 0.000 description 5
- 230000003872 anastomosis Effects 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000006227 byproduct Substances 0.000 description 5
- 229940012444 factor xiii Drugs 0.000 description 5
- 230000002779 inactivation Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000002458 infectious effect Effects 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 238000001728 nano-filtration Methods 0.000 description 5
- 238000009928 pasteurization Methods 0.000 description 5
- 229940012957 plasmin Drugs 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000029663 wound healing Effects 0.000 description 5
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 4
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229920004890 Triton X-100 Polymers 0.000 description 4
- 239000013504 Triton X-100 Substances 0.000 description 4
- 229930003448 Vitamin K Natural products 0.000 description 4
- 239000003114 blood coagulation factor Substances 0.000 description 4
- 238000011088 calibration curve Methods 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- 235000019168 vitamin K Nutrition 0.000 description 4
- 239000011712 vitamin K Substances 0.000 description 4
- 150000003721 vitamin K derivatives Chemical class 0.000 description 4
- 229940046010 vitamin k Drugs 0.000 description 4
- 241001269524 Dura Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 108010022999 Serine Proteases Proteins 0.000 description 3
- 102000012479 Serine Proteases Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 230000023555 blood coagulation Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000013024 dilution buffer Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 230000002439 hemostatic effect Effects 0.000 description 3
- 230000000415 inactivating effect Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000002047 thymogen Effects 0.000 description 3
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 3
- 229960000401 tranexamic acid Drugs 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 108010088842 Fibrinolysin Proteins 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 241000702617 Human parvovirus B19 Species 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 108010017446 glycyl-prolyl-arginyl-proline Proteins 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 239000006193 liquid solution Substances 0.000 description 2
- 210000004779 membrane envelope Anatomy 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- WXPZDDCNKXMOMC-AVGNSLFASA-N (2s)-1-[(2s)-2-[[(2s)-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carboxylic acid Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@H](C(O)=O)CCC1 WXPZDDCNKXMOMC-AVGNSLFASA-N 0.000 description 1
- BPPVUXSMLBXYGG-UHFFFAOYSA-N 4-[3-(4,5-dihydro-1,2-oxazol-3-yl)-2-methyl-4-methylsulfonylbenzoyl]-2-methyl-1h-pyrazol-3-one Chemical compound CC1=C(C(=O)C=2C(N(C)NC=2)=O)C=CC(S(C)(=O)=O)=C1C1=NOCC1 BPPVUXSMLBXYGG-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241001091551 Clio Species 0.000 description 1
- 102100023804 Coagulation factor VII Human genes 0.000 description 1
- FBPFZTCFMRRESA-ZXXMMSQZSA-N D-iditol Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-ZXXMMSQZSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 101150117357 F2 gene Proteins 0.000 description 1
- 108010014172 Factor V Proteins 0.000 description 1
- 108010023321 Factor VII Proteins 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- LLEUXCDZPQOJMY-AAEUAGOBSA-N Glu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)N)C(O)=O)=CNC2=C1 LLEUXCDZPQOJMY-AAEUAGOBSA-N 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- MXRIRQGCELJRSN-UHFFFAOYSA-N O.O.O.[Al] Chemical compound O.O.O.[Al] MXRIRQGCELJRSN-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229920004897 Triton X-45 Polymers 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 206010051373 Wound haemorrhage Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 229960003589 arginine hydrochloride Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 244000078885 bloodborne pathogen Species 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229940012413 factor vii Drugs 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 244000309711 non-enveloped viruses Species 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000002616 plasmapheresis Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000013037 reversible inhibitor Substances 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 108010014252 thymogen Proteins 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- STCOOQWBFONSKY-UHFFFAOYSA-N tributyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 238000007631 vascular surgery Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/363—Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4833—Thrombin (3.4.21.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/0005—Ingredients of undetermined constitution or reaction products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0015—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
- A61L24/106—Fibrin; Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/75—Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/30—Compounds of undetermined constitution extracted from natural sources, e.g. Aloe Vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21005—Thrombin (3.4.21.5)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Surgery (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Materials Engineering (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Description
第VIII因子枯渇クリオプレシピテート(FDC)の調製:
FVIII枯渇クリオプレシピテート(FDC)は、第VIII因子(FVIII)の製造プロセスの副産物である。製造プロセス中、低い塩濃度の条件下、14〜18℃の範囲内の温度でエタノールを添加した後、遠心分離することにより、フィブリノゲン、フィブロネクチン、第XIII因子、並びにプラスミン及び/又はプラスミノゲンなどのプロテアーゼが、再懸濁クリオプレシピテートから沈殿する。遠心分離工程に先立って、上記の再懸濁中に水酸化アルミニウム[Al(OH)3]を添加することにより)、第II因子、第VII因子及び第X因子などのビタミンK依存性凝固因子が水酸化アルミニウムと共に沈殿する。水酸化アルミニウム沈殿物(即ち、FDC)を、第VIII因子含有上清から分離し、下記に記載する実験にて使用した。
凝固時間の試験によるフィブリノゲンレベルの決定(Clauss法)
試料のフィブリノゲン(mg/ml)=(較正曲線からのmg/100ml×希釈倍数)/100。
非補充及び血漿補充フィブリノゲン試料を、以下のように調製した。120ml及び90mlの再懸濁緩衝液(0.7% NaCl、0.295%クエン酸三ナトリウムpH7.4)を、それぞれ2つの異なるビーカーA及びB内で34℃に予熱した。次いで、7.5mlの2%アルハイドロゲル[Al(OH)3]及び2.25mlの、ビーズに結合したトラネキサム酸(TEA)(これは、概して国際特許出願公開第2013/001524号に開示されているように、特にFDC調製物からプラスミン及び/又はプラスミノゲンを除去する)を連続的に撹拌しながら各ビーカーに添加した。30mlのプールしたヒト血漿(クリオプア血漿)をビーカーB内の混合物に添加した。
上記の実施例1の非補充(A)及び血漿補充(B)フィブリノゲン試料を、以下のように、フィブリノゲン安定性に関して試験した。
クリオプレシピテートから得られた濃縮フィブリノゲン調製物に血漿を添加して、タンパク質安定性に対する血漿の効果(例えば、タンパク質分解の低下)を評価した。クリオプレシピテートを溶解し、水酸化アルミニウムを添加し、S/D処理に供し、油抽出及び逆相カラムによりS/D物質を除去する(概して、国際公開第93/05822号及び同第94/22503号に記載されているように)ことによって、クリオプレシピテート由来の濃縮フィブリノゲン調製物を調製した。この実施例では、濃縮フィブリノゲン調製物は、プラスミン/プラスミノゲンを除去するためのTEAに供されず、またプロテアーゼ阻害剤にも供されなかった。濃縮フィブリノゲン調製物(約30mg/ml)の2つのバッチからの試料を収集し、添加された血漿と共に又は添加された血漿なしに、37℃(又は凍結状態に維持)でインキュベートし、SDS−PAGEを使用してタンパク質の完全性に関して試験した。使用した血漿は、ドナーから血漿交換により収集した血漿単位であった。希釈緩衝液の組成は、120mM NaCl、10mMクエン酸ナトリウム、120mMグリシン、95mMアルギニン塩酸塩、1mM塩化カルシウムであった。
I.37℃保存−100μlフィブリノゲン調製物+100μl血漿。
II.37℃保存−100μlフィブリノゲン調製物+100μl希釈緩衝液。
III−80℃保存−100μlフィブリノゲン調製物+100μl血漿。
IV.−80℃保存−100μlフィブリノゲン調製物+100μl希釈緩衝液。
950ml DDWを50ml MOPS泳動緩衝液X20(Life Technologies,NP0001)で希釈することにより1リットルの泳動緩衝液を調製した。試料ローディング混合物の組成を、表2に示す。
ヒト血清血漿中のIgGクラスパルボウイルスB19抗体を検出するためにパルボウイルスB19−IgG ELISAキット(BIOTRIN)、サンドイッチELISAを用いて、B19特異的抗体の定量を行った。アッセイは製造者の指示書に従って行った。試料A及びBに関して得られた結果を、表3に要約する。
実施例1の血漿補充フィブリノゲンを、2つの直交性ウイルス不活化工程と、プラスミン及びプラスミノゲンの除去と、濃縮と、調製と、滅菌濾過とを含むように、処理した(基本的に、国際特許出願公開第2013/001524号におけるように)。最終的な製剤は、50〜90mg/mlの範囲内のフィブリノゲン濃度を含んでいた。
ラット腎臓止血モデルは、止血試験のための一般的なモデルである(Raccuia JS et al.,Comparative efficacy of topical hemostatic agents in a rat kidney model.Am J Surg.1992.163(2):234〜8)。手短には、腎臓を腹膜側から解剖して出し、その周囲にパッドを置いて血液を吸い上げた。腎臓に供給する血管上にクランプを置き、腎臓を通して横方向の切断部を作製した。血漿補充フィブリノゲン成分(実施例5のように調製)及びトロンビン成分(VICELフィブリンシーラントにおけるトロンビン成分のような)を含むシーラント製剤を、1:1の比で使用した。シーラントを適用し、クランプを除去した。出血を1時間の間評価した後、出血の総量を秤量した。続いて、シーラントを擦り落とし、出血を再開させ、低、中又は高として定量した(出血の可能性が尚存在するか否かを評価するために)。全てのラットに300IUヘパリン/kg動物体重を注入して、自発的な止血を防止した。
(1) フィブリノゲン製剤の調製方法であって、
濃縮フィブリノゲン調製物と血漿源とを混合する工程を含む、方法。
(2) 前記濃縮フィブリノゲン調製物が、血液又は血液画分に由来する、実施態様1に記載の方法。
(3) 前記濃縮フィブリノゲン調製物中のフィブリノゲン濃度が、約10mg/ml〜200mg/mlの範囲内である、実施態様1又は2に記載の方法。
(4) 前記濃縮フィブリノゲン調製物中のフィブリノゲン濃度が、約10mg/ml〜150mg/mlの範囲内である、実施態様1又は2に記載の方法。
(5) 前記濃縮フィブリノゲン調製物がクリオプレシピテートである、実施態様1〜4のいずれかに記載の方法。
(7) 前記濃縮フィブリノゲン調製物と前記血漿とが、約1:1の比で混合される、実施態様1〜6のいずれかに記載の方法。
(8) 血漿補充フィブリノゲン製剤。
(9) 実施態様1〜7のいずれかに記載の方法に従って得ることが可能なフィブリノゲン製剤。
(10) フィブリンシーラントの成分として使用するための、実施態様8又は9に記載のフィブリノゲン製剤。
(12) 血漿補充フィブリノゲン成分及びトロンビン成分を表面に適用することを含む、前記表面におけるシーラントの調製方法。
(13) 血漿補充フィブリノゲンから調製されたフィブリンモノマーを含む、シーラント製剤。
(14) 実施態様8、9、11又は13のいずれかに記載の製剤を含む容器。
(15) 実施態様14に記載の容器及び任意に使用説明書を含む、キット。
(17) 有効量の実施態様8、9又は11のいずれかに記載の製剤を、トロンビン製剤と共に前記対象に適用することを含む、実施態様16に記載の方法。
(18) フィブリンモノマーを含む血漿補充製剤。
Claims (5)
- 血漿源を補充してなる、少なくとも5日間の保存のために安定化された、フィブリノゲン製剤であって、
前記フィブリノゲン製剤が、血漿クリオプレシピテート、血漿酸沈殿物、血漿冷却沈殿物、血漿水酸化アルミニウム沈殿物、血漿グリシン沈殿物、血漿エタノール沈殿物、血漿ヘパリン沈殿物、及びこれらの組み合わせからなる群から選択される濃縮フィブリノゲン調製物を含有し、
前記血漿源が、動物血漿、クリオプア血漿、回収された血漿、トロンビン枯渇血漿、因子枯渇血漿、血漿交換により収集された血漿、及びこれらの組み合わせからなる群から選択されるプールした血漿源であり、
前記濃縮フィブリノゲン調製物と前記血漿源との比が、約3:1〜約1:3であり、
前記フィブリノゲン製剤は、血小板に富んだ血漿を含有せず、
前記血漿源が前記クリオプア血漿である、
フィブリンシーラントの成分として使用するための、フィブリノゲン製剤。 - 請求項1に記載のフィブリノゲン製剤を含む、シーラント製剤。
- 請求項1に記載のフィブリノゲン製剤を含む、容器。
- 請求項2に記載のシーラント製剤を含む、容器。
- 請求項3又は4に記載の容器、及び任意に使用説明書を含む、キット。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461945167P | 2014-02-27 | 2014-02-27 | |
IL231230 | 2014-02-27 | ||
US61/945,167 | 2014-02-27 | ||
IL231230A IL231230A0 (en) | 2014-02-27 | 2014-02-27 | Fibrinogen preparation |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016554359A Division JP6563412B2 (ja) | 2014-02-27 | 2015-02-25 | 血漿補充製剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019196388A JP2019196388A (ja) | 2019-11-14 |
JP6812511B2 true JP6812511B2 (ja) | 2021-01-13 |
Family
ID=51418092
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016554359A Expired - Fee Related JP6563412B2 (ja) | 2014-02-27 | 2015-02-25 | 血漿補充製剤 |
JP2019135198A Active JP6812511B2 (ja) | 2014-02-27 | 2019-07-23 | フィブリノゲン製剤 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016554359A Expired - Fee Related JP6563412B2 (ja) | 2014-02-27 | 2015-02-25 | 血漿補充製剤 |
Country Status (8)
Country | Link |
---|---|
US (1) | US10806755B2 (ja) |
EP (1) | EP3110842A1 (ja) |
JP (2) | JP6563412B2 (ja) |
CN (1) | CN106061519A (ja) |
AU (2) | AU2015221786B2 (ja) |
CA (1) | CA2939555A1 (ja) |
IL (1) | IL231230A0 (ja) |
WO (1) | WO2015128858A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL231230A0 (en) | 2014-02-27 | 2014-08-31 | Omrix Biopharmaceuticals Ltd | Fibrinogen preparation |
EP3258945B1 (en) | 2015-02-16 | 2020-10-07 | Nayacure Therapeutics Ltd. | Modified blood clots |
IL244922A0 (en) * | 2016-04-05 | 2016-07-31 | Omrix Biopharmaceuticals Ltd | Device and method for sample preparation |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2916711A1 (de) | 1979-04-25 | 1980-11-06 | Behringwerke Ag | Blutgerinnungsfaktoren und verfahren zu ihrer herstellung |
US4455300A (en) | 1980-03-05 | 1984-06-19 | Cutter Laboratories, Inc. | Fibronectin compositions |
US4341764A (en) | 1980-03-05 | 1982-07-27 | Cutter Laboratories, Inc. | Method of preparing fibronectin and antihemophilic factor |
US4627879A (en) * | 1984-09-07 | 1986-12-09 | The Trustees Of Columbia University In The City Of New York | Fibrin adhesive prepared as a concentrate from single donor fresh frozen plasma |
DE3622642A1 (de) | 1986-07-05 | 1988-01-14 | Behringwerke Ag | Einkomponenten-gewebekleber sowie verfahren zu seiner herstellung |
US5318524A (en) | 1990-01-03 | 1994-06-07 | Cryolife, Inc. | Fibrin sealant delivery kit |
US5792835A (en) | 1991-09-05 | 1998-08-11 | Baxter International Inc. | Method of preparing a topical fibrinogen complex |
CZ280540B6 (cs) | 1991-09-27 | 1996-02-14 | Opperbas Holding B.V. | Tkáňové lepidlo obsahující kryoprecipitát, způsob jeho výroby a použití aprotininu, proteázy z hadího jedu a batroxobinu pro jeho přípravu |
DE4202667C1 (ja) | 1992-01-29 | 1993-05-13 | Behringwerke Ag, 3550 Marburg, De | |
CN1091315A (zh) | 1992-10-08 | 1994-08-31 | E·R·斯奎布父子公司 | 血纤维蛋白封闭剂组合物及其使用方法 |
CA2159469C (en) | 1993-03-30 | 2004-06-22 | Uri Martinowitz | Two component fibrin glue |
ES2139227T5 (es) | 1994-07-14 | 2011-05-04 | Caf-Dcf Département Central De Fractionnement De La Croix Rouge S.C.R.L. | Concentrado de fibrinógeno obtenido de plasma sanguíneo, procedimiento e instalación para su preparación. |
JP2002514948A (ja) * | 1996-02-20 | 2002-05-21 | コーヒージョン・コーポレーション | 組織シーラント組成物とその使用方法 |
WO2000062828A1 (en) * | 1996-04-30 | 2000-10-26 | Medtronic, Inc. | Autologous fibrin sealant and method for making the same |
WO1998055140A1 (en) * | 1997-06-05 | 1998-12-10 | Omrix Biopharmaceuticals S.A. | Fibrinogen concentrate from human plasma |
GB9711927D0 (en) | 1997-06-09 | 1997-08-06 | Bristol Myers Squibb Co | Compositions useful as fibrin sealants |
US20040092451A1 (en) * | 1997-10-17 | 2004-05-13 | Lou Blasetti | Precipitation of growth-factor-enriched fibrinogen concentrate from platelet rich plasma |
EE05485B1 (et) | 2001-05-21 | 2011-10-17 | Omrix Biopharmaceuticals S.A. | Plasmi(i)n(ogeen)i eemaldamine valgulahustest |
IL161262A0 (en) * | 2001-10-03 | 2004-09-27 | Christopher J Woolverton | Storage-stable human fibrinogen solutions |
IL162369A0 (en) | 2001-12-04 | 2005-11-20 | Woolverton Christopher J | Storage-stable fibrin sealant |
DE10261126A1 (de) * | 2002-08-13 | 2004-03-04 | Aventis Behring Gmbh | Lagerungsstabile, flüssige Fibrinogen-Formulierung |
US20070014780A1 (en) * | 2005-07-13 | 2007-01-18 | Statseal | Storage-stable human fibrinogen solutions |
WO2007127841A2 (en) * | 2006-04-26 | 2007-11-08 | Arteriocyte Medical Systems, Inc. | Compositions and methods of preparation thereof |
CA2714281A1 (en) * | 2008-03-28 | 2009-10-01 | Research Foundation For Medical Devices | Method of viral inactivation of biological fluids by solvent/detergent-treatment |
HUE028626T2 (en) * | 2008-06-23 | 2016-12-28 | Bio-Products & Bio-Engineering Ag | Stable, functionally intact, virus-inactivated fibrinogen during storage |
CN102089322B (zh) * | 2008-07-09 | 2015-09-23 | 普罗菲布瑞克斯公司 | 重组纤维蛋白原 |
US8367802B2 (en) | 2009-06-18 | 2013-02-05 | Biomedica Management Corporation | Method to produce fibrin monomer in acid media for use as tissue sealant |
IL213864A0 (en) | 2011-06-30 | 2011-08-31 | Omrix Biopharmaceuticals Ltd | Method for removing a lytic enzyme from a heterogeneous mixture |
PL218235B1 (pl) * | 2011-09-12 | 2014-10-31 | Henryk Bursig | Nośnik fibrynowy autologiczny i allogeniczny, sposób jego otrzymywania i zastosowanie nośnika fibrynowego do przeszczepu komórek, zwłaszcza ludzkich |
IL231230A0 (en) | 2014-02-27 | 2014-08-31 | Omrix Biopharmaceuticals Ltd | Fibrinogen preparation |
-
2014
- 2014-02-27 IL IL231230A patent/IL231230A0/en unknown
-
2015
- 2015-02-25 JP JP2016554359A patent/JP6563412B2/ja not_active Expired - Fee Related
- 2015-02-25 CN CN201580010752.9A patent/CN106061519A/zh active Pending
- 2015-02-25 EP EP15717659.5A patent/EP3110842A1/en not_active Withdrawn
- 2015-02-25 US US14/631,099 patent/US10806755B2/en active Active
- 2015-02-25 AU AU2015221786A patent/AU2015221786B2/en not_active Ceased
- 2015-02-25 WO PCT/IL2015/000010 patent/WO2015128858A1/en active Application Filing
- 2015-02-25 CA CA2939555A patent/CA2939555A1/en not_active Abandoned
-
2019
- 2019-07-23 JP JP2019135198A patent/JP6812511B2/ja active Active
- 2019-07-26 AU AU2019208251A patent/AU2019208251B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
IL231230A0 (en) | 2014-08-31 |
US10806755B2 (en) | 2020-10-20 |
CA2939555A1 (en) | 2015-09-03 |
US20150238529A1 (en) | 2015-08-27 |
WO2015128858A8 (en) | 2017-03-16 |
JP2019196388A (ja) | 2019-11-14 |
AU2015221786B2 (en) | 2019-05-02 |
EP3110842A1 (en) | 2017-01-04 |
JP6563412B2 (ja) | 2019-08-21 |
CN106061519A (zh) | 2016-10-26 |
AU2015221786A1 (en) | 2016-09-08 |
JP2017506657A (ja) | 2017-03-09 |
AU2019208251A1 (en) | 2019-08-15 |
AU2019208251B2 (en) | 2020-10-22 |
WO2015128858A1 (en) | 2015-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6812511B2 (ja) | フィブリノゲン製剤 | |
AU2013203357B2 (en) | A method of purifying therapeutic proteins | |
ES2586698T3 (es) | Proceso para la producción de fibrinógeno | |
AU2003244850B2 (en) | Processes for the preparation of fibrinogen | |
AU2008230476B2 (en) | Solid fibrinogen preparation | |
CA2728358C (en) | Storage-stable, functionally intact fibrinogen | |
JP2001261574A (ja) | トロンビン製剤およびその製造方法 | |
JP7387715B2 (ja) | 安定した液体トロンビン組成物 | |
WO2015097687A1 (en) | One component fibrin glue comprising zymogens | |
EP3122260A1 (en) | Device and method for preparing and administering one-component fibrin sealant | |
JP6018299B2 (ja) | 単一ドナーのトロンビン血清を調製する方法および機器 | |
Chabbat et al. | Properties of a new fibrin glue stable in liquid state | |
JP2005505581A (ja) | 貯蔵安定なヒトフィブリノーゲン溶液 | |
RU2648517C1 (ru) | Способ получения лиофилизированного препарата активированного протромбинового комплекса, обладающего фактор viii-шунтирующей активностью | |
RU2559576C1 (ru) | Способ получения вирусбезопасного полного протромбинового комплекса | |
ES2711455T3 (es) | Un método de purificación de proteínas terapéuticas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190723 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A132 Effective date: 20200428 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200722 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201201 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201216 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6812511 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |